Telmisartan, Ramipril, or both in patients at high risk for vascular events
Authors
Dyal L.
Schumacher H.
Pogue J.
Sleight P.
Dagenais G.
Copland I.
ONTARGET Investigators
Teo K.
Yusuf S.
Anderson Craig
Type of Publication
Journal Article
Journal
New England Journal of Medicine
